Avacopan

Phase 3

Amgen Inc. (AMGN)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q3 '27

AMGNPhase 3$219.9B

Avacopan Phase 3 Est. Readout

Avacopan• Vasculitis19

Q3 2027~QEstimated

CT.gov

00%

Competitive Landscape

0 competitors in Vasculitis

View Full Landscape

Drug Information

Target Indication

Vasculitis

Clinical Trial

NCT06321601

Last updated: 1/8/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMAPending

Vynpenta (previously AvacopanChemoCentryx)

Induction of response in adult patients with granulomatosis with polyangiitis (Wegener’s) (GPA) or microscopic polyangiitis (MPA)

Orphan

View on EMA

EMA1/11/2022

Tavneos

Tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).

OrphanPRIME

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

AMGN

Amgen Inc.

Biological Products, (No Diagnostic Substances)•North America•NASDAQ

Related Pipeline

Denosumab (AMG 162)Phase 3

Postmenopausal Osteoporosis

TarlatamabPhase 3

Small Cell Lung Cancer

romosozumab HCP administration with PFSPhase 3

Post-Menopausal Osteoporosis

Etanercept LiquidPhase 3

Rheumatoid Arthritis

PegaspargasePhase 3

Acute Lymphoblastic Leukemia

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts